Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Thorac Oncol. 2017 Jun 10;12(11):e175–e177. doi: 10.1016/j.jtho.2017.06.002

Figure 2. Use of ALK inhibitors, anti-cancer, and palliative therapies for the first 5 years (60 months) after initiation of crizotinib in 26 patients with advanced ALK-rearranged lung cancers.

Figure 2

The type of ALK TKI, chemotherapy, or best supportive care are indicated by different colors. Progressive disease by RECIST is indicated by (P), toxicity to crizotinib by (T), use of radiotherapy by (X), loss of patient follow-up by (L), death by (D) and ongoing therapy/survival by (+).